Abarelix
FDA-approved product (powder, intramuscular), marketed as Plenaxis.
- Registered studies
- 5
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Neoplasm
Indications ChEMBL records as approved, from FDA and DailyMed labels.
- WHO therapeutic group
- Other hormone antagonists and related agents
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA67.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli53.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae34.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis62.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
5registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Abarelix with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- UrsodiolExisting use: Biliary liver cirrhosis, Primary biliary cirrhosis69.2% AI-predicted activityagainst MRSA50+ registered studies
- OlaparibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 9 more69.2% AI-predicted activityagainst MRSA50+ registered studies
- Ganirelix AcetateExisting use: Female infertility, Positive regulation of ovulation, Reproductive Techniques, Assisted69.1% AI-predicted activityagainst MRSA50+ registered studies
- DanicopanExisting use: Acquired paroxysmal nocturnal hemoglobinuria, Hemoglobinuria, Paroxysmal, Hemolysis68.7% AI-predicted activityagainst MRSA30 registered studies
- Simeprevir SodiumExisting use: Chronic hepatitis C virus infection68.6% AI-predicted activityagainst MRSANo documented evidence found
- Lanreotide AcetateExisting use: Acromegaly, Carcinoid syndrome68.3% AI-predicted activityagainst MRSA50+ registered studies
- Cholic AcidExisting use: Abnormality of the gastrointestinal tract, Inborn errors of metabolism, Liver disease and 1 more68.0% AI-predicted activityagainst MRSA50+ registered studies
- EptifibatideExisting use: Acute coronary syndrome, Acute myocardial infarction, Intermediate coronary syndrome and 2 more67.8% AI-predicted activityagainst MRSA35 registered studies
- EverolimusExisting use: Adenoma sebaceum, Anaplastic astrocytoma, Angiomyolipoma and 18 more67.5% AI-predicted activityagainst MRSA50+ registered studies
- Paliperidone PalmitateExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.3% AI-predicted activityagainst MRSA50+ registered studies
- PaliperidoneExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.2% AI-predicted activityagainst MRSA50+ registered studies
- Ozanimod HydrochlorideExisting use: Multiple sclerosis, Relapsing-remitting multiple sclerosis, Ulcerative colitis66.8% AI-predicted activityagainst MRSA7 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
NCT06379217 · start 2024-07-29
Registered record
- Registry ID
- NCT06379217
- Conditions
- Metastatic Neuroendocrine Prostate Cancer
- Interventions
- [68Ga]Ga-PSMA-11; [68Ga]GA-DOTA-TATE; [68Ga]Ga-NeoB; [177Lu]Lu-PSMA-617; [177Lu]Lu-DOTA-TATE; [177Lu]Lu-NeoB; L-Lysine HCl-L-Arginine HCl, 2.5 %,; Gonadotropin-releasing hormone (GnRH) analogues; GnRH antagonists; Antiemetics & antinauseants; Metoclopramide
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Active not recruiting
- Start
- 2024-07-29
- Completion
- 2026-08-31
- Enrolment
- 31
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMetastatic Neuroendocrine Prostate CancerIntervention[68Ga]Ga-PSMA-11; [68Ga]GA-DOTA-TATE; [68Ga]Ga-NeoB; [177Lu]Lu-PSMA-617 +7 morePhasePhase 1Registry statusActive not recruitingDiagnosis of Pelvic Endometriosis in MRI
NCT06157528 · start 2023-12-20
Registered record
- Registry ID
- NCT06157528
- Conditions
- Endometriosis
- Interventions
- Magnetic resonance imaging
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Not yet recruiting
- Start
- 2023-12-20
- Completion
- 2029-12
- Enrolment
- 100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEndometriosisInterventionMagnetic resonance imagingPhaseNot applicableRegistry statusNot yet recruitingThe Plenaxis® Experience Study
NCT00103623 · start 2004-06
Registered record
- Registry ID
- NCT00103623
- Conditions
- Prostate Cancer
- Interventions
- Plenaxis
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Suspended
- Start
- 2004-06
- Completion
- 2008-12
- Enrolment
- 2,000
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstate CancerInterventionPlenaxisPhasePhase 4Registry statusSuspendedStudy of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy
NCT00100243 · start 2004-05
Registered record
- Registry ID
- NCT00100243
- Conditions
- Prostate Cancer
- Interventions
- Plenaxis
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2004-05
- Completion
- 2005-09
- Enrolment
- 22
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstate CancerInterventionPlenaxisPhasePhase 2Registry statusCompletedAbarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer
NCT00841113 · start 1999-01
Registered record
- Registry ID
- NCT00841113
- Conditions
- Prostate Cancer
- Interventions
- Abarelix; Goserelin plus Bicalutamide
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 1999-01
- Completion
- 2003-02
- Enrolment
- 177
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstate CancerInterventionAbarelix; Goserelin plus BicalutamidePhasePhase 3Registry statusCompleted